Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640275 | 0.96 | GLP1R (0.46) | FAAHEPHX2ALDH1A1NAMPTTSHR | |
| SCHEMBL13880451 | 0.92 | FAAH (0.51) | FAAHALDH1A1NAMPTTSHRCASP1 | |
| SCHEMBL13640257 | 0.89 | FAAH (0.50) | FAAHEPHX2TSHRCASP2GLP1R | |
| SCHEMBL17167854 | 0.89 | FAAH (0.46) | FAAHEPHX2TSHRCASP2GLP1R | |
| SCHEMBL13640253 | 0.89 | FAAH (0.53) | FAAHEPHX2CASP2GLP1RMEN1 | |
| SCHEMBL13640268 | 0.87 | GLP1R (0.48) | FAAHEPHX2TSHRCASP2GLP1R | |
| SCHEMBL13640271 | 0.87 | GLP1R (0.48) | FAAHEPHX2TSHRCASP2GLP1R | |
| SCHEMBL13640260 | 0.87 | MEN1 (0.49) | FAAHEPHX2TSHRCASP2GLP1R | |
| SCHEMBL19645170 | 0.86 | ADRA1A (0.53) | FAAHEPHX2GLP1R | |
| SCHEMBL13640267 | 0.85 | ADRA1A (0.47) | FAAHCASP2GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012398-B2 | Acylated exendin-4 compounds | NOVO NORDISK A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| US-20120283170-A1 | Acylated Exendin-4 Compounds | NOVO NORDISK A/S (DK) | 2012-11-08 | — | — | US | disclosed |
| US-20090111730-A1 | Polypeptide protracting tags | NOVO NORDISK A/S (DK) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283170-A1 | Acylated Exendin-4 Compounds | GLP1R, VIP, IAPP | FAAH 163/4885EPHX2 1620/4885ALDH1A1 4133/4885 |
| US-20090111730-A1 | Polypeptide protracting tags | LNPEP, FGB, ENPEP | FAAH 2903/4885EPHX2 4199/4885ALDH1A1 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.